There are a few ways exosomes can be delivered and one of the most effective ways for systemic therapy is thru Intravenous. This therapy is where exosomes are delivered Intravenous (IV) that introduces purified, cell-free extracellular vesicles—typically derived from mesenchymal stem cells—directly into the bloodstream for systemic circulation. The process is straightforward, minimally invasive, and performed in a clinical setting under medical supervision. Typical steps in the delivery process:
Once the infusion finishes, the IV is removed. Most people return to normal activities the same day. Mild temporary effects such as slight fatigue or a small bruise at the insertion site can occur. Hydration is encouraged, and follow-up guidance is provided.
Because exosomes are nano-sized (approximately 30–150 nanometers), they circulate freely and can reach multiple tissues without the lung-trapping issues sometimes seen with larger living cells. This systemic route is chosen when the goal is whole-body support rather than a highly localized effect.
Improvements we have experienced in the IV delivery allows the bioactive cargo of exosomes—growth factors, cytokines, proteins, lipids, mRNA, and microRNAs—to interact with cells throughout the body. Proposed mechanisms include enhanced cellular communication, modulation of inflammation, support for tissue repair processes, and promotion of a more regenerative microenvironment. Areas of potential improvement commonly discussed include:
Improvements, when they occur, are typically gradual. Some people notice changes within days to weeks, while fuller effects may develop over several weeks to months as cellular processes respond. Outcomes are not guaranteed and depend on many factors.
A substantial and rapidly growing body of scientific literature examines the biology and potential therapeutic applications of stem cell–derived exosomes. According to resources compiled, there are more than 43,000 peer-reviewed published studies on stem cell exosomes from the past five years alone, with hundreds more appearing regularly. The research landscape focuses on regenerative mechanisms, anti-inflammatory effects, tissue repair, and related pathways. While many studies are preclinical (laboratory or animal models) and human clinical data remain limited and heterogeneous, the volume of ongoing investigation underscores strong scientific interest in the signaling capabilities of these vesicles.
IV exosome therapy is investigational and studies continue to support the therapy as positive. There are currently no FDA-approved exosome products for any medical condition. Product quality, sterility, characterization, and clinical oversight are essential for safety. Long-term safety data continue to accumulate.
At All U Health, every candidate undergoes individualized assessment. We emphasize transparent discussion of realistic expectations, the current state of evidence, and integration with other evidence-informed care when appropriate.
© 2026 All U Health, All rights reserved.